Research exploring whether garlic-derived organosulfur compounds can inhibit 5-alpha reductase enzymes (5AR1 and 5AR2) to reduce dihydrotestosterone production, potentially benefiting benign prostatic hyperplasia. The study investigates ajoene and related compounds in mammalian cell models using LC-MS/MS steroid conversion assays.
This research investigates the potential of natural garlic organosulfur compounds, particularly ajoene and its analogues, to inhibit the catalytic activity of 5-alpha reductase type 1 (5AR1) and type 2 (5AR2). These enzymes convert testosterone to dihydrotestosterone, a hormone implicated in benign prostatic hyperplasia and prostate cancer. By blocking this conversion, garlic compounds may offer a natural approach to managing prostate health conditions, potentially serving as an alternative or complement to existing pharmaceutical treatments such as finasteride.
The research addresses an underexplored area at the intersection of natural product biochemistry and steroid metabolism. Garlic consumption has been associated with improved prostate disease parameters, yet the specific molecular mechanisms remain unclear. This work aims to identify and characterise which organosulfur compounds are responsible for these effects and how they interact with 5AR enzymes.
Research approach:
Proposed mechanism of action:
This research is at an early exploratory stage. The hypothesis is supported by published evidence showing that garlic extracts reduced prostate weight and DHT levels in BPH-induced animal models, and that ajoene binds covalently to cysteine residues in other proteins. However, the specific inhibitory effects of ajoene and analogues on 5AR1 and 5AR2 have not yet been directly validated.
The proposed two-year study would establish proof-of-concept through in vitro enzyme inhibition assays and cell-based models. Funding is required for LC-MS/MS analysis, tissue culture reagents, chemical synthesis of natural tetrasulfides, an automated cell counter, and key personnel. Upon completion, findings could support further development toward nutraceutical or pharmaceutical applications for prostate health.
Stellenbosch University is a comprehensive public research university in South Africa’s Western Cape with a strong research culture. Industry collaboration runs through Innovus, the university’s technology transfer office, and SU LaunchLab, which incubates spinouts and partner ventures. Field-scale testing uses university experimental farms at Welgevallen and Mariendahl, and clinical translation is supported by the Biomedical Research Institute on the Tygerberg medical campus alongside the teaching hospital. Research is backed by competitive national funding, including the National Research Foundation and the South African Medical Research Council. Innovus manages IP, licensing, and company formation to streamline engagement.